AZNAstraZenecaRunning, no new patients
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Locally Advanced or Metastatic Solid Tumours
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 126 (final count)
- Started
- Dec 10, 2021
- Main results expected
- Oct 7, 2024
- Fully finished
- Nov 30, 2026
- Results posted
- Nov 26, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs)
Measured over: From Cycle 1 Day 1 (each cycle was 28 days in length) until Day 90 (post last dose of study intervention), up to 34 months
Overall Survival at 12 Months (OS-12)
Measured over: At 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04999969 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC